Goldman Sachs’s Heron Therapeutics HRTX Stock Holding History

Goldman Sachs’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-38,500	Closed	-$697K	–	6107
2017 Q4	$697K	Buy	38,500 +1,100	+3%	+$17.9K	﹤0.01%	4570
2017 Q3	$604K	Buy	37,400 +35,700	+2,100%	+$560K	﹤0.01%	4968
2017 Q2	$24K	Sell	1,700 -5,500	-76%	-$79.7K	﹤0.01%	6522
2017 Q1	$108K	Buy	7,200 +6,000	+500%	+$83K	﹤0.01%	6033
2016 Q4	$16K	Sell	1,200 -4,300	-78%	-$67.5K	﹤0.01%	6692
2016 Q3	$95K	Buy	5,500 +3,000	+120%	+$55.7K	﹤0.01%	6248
2016 Q2	$45K	Sell	2,500 -54,500	-96%	-$1.06M	﹤0.01%	6462
2016 Q1	$1.08M	Buy	57,000 +43,100	+310%	+$850K	﹤0.01%	4017
2015 Q4	$371K	Sell	13,900 -996,500	-99%	-$26.6M	﹤0.01%	5166
2015 Q3	$24.7M	Buy	+1,010,400	New	+$33.7M	0.01%	1572

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Goldman Sachs's HRTX Position: Q2 2026 in Review

Goldman Sachs increased its Heron Therapeutics (HRTX) stake by 26% in Q2 2026, buying an estimated $219K and bringing the position to 1,329,754 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #5624.

Goldman Sachs first reported a position in HRTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $36.1M in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Goldman Sachs held 1,329,754 shares of Heron Therapeutics worth $568K as of Q2 2026.
Goldman Sachs bought 272,810 Heron Therapeutics shares in Q2 2026, an estimated $219K.
Heron Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5624 holding.
Goldman Sachs first reported a position in Heron Therapeutics in Q1 2014 and has held it in 47 quarters since.
Goldman Sachs's Heron Therapeutics position peaked at $36.1M in Q4 2019.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.